ORIGINAL ARTICLE

Polypoidal choroidal vasculopathy—characteristics and response to treatment with bevacizumab in caucasian patients

Fidaa El Zhalka1*, Elad Moisseiev1,2 and Alexander Rubowitz1,2

Abstract
Purpose: To investigate the features and treatment response in Caucasian patients with polypoidal choroidal vasculopathy (PCV), initially treated with bevacizumab.

Methods: 45 eyes of 43 treatment-naïve patients with PCV were included in this retrospective study, all uniformly initially treated with three bevacizumab injections monthly. OCT characteristics and clinical parameters were recorded and analyzed at presentation, after the initial 3 bevacizumab injections and at the final follow up period.

Results: Following 3 monthly bevacizumab injections visual acuity significantly improved with a mean gain of one line of vision. Central macular thickness (CMT) significantly improved from a mean of 402.1 ± 130.8 μm at presentation to 322.0 ± 96.8 μm (p < 0.01). Subretinal fluid, intraretinal fluid and submacular hemorrhage significantly improved. 53% were later switched to aflibercept and showed better response in the central macular thickness in comparison to those in which bevacizumab injections were continued. No correlation was found between the presence of pachyvessels or increased choroidal thickness and the improvement in VA or CMT.

Conclusion: Fixed first-line treatment with intravitreal bevacizumab monotherapy in non-Asian PCV patients achieves satisfactory visual and anatomical outcomes.

Introduction
Polypoidal choroidal vasculopathy (PCV) is considered to be a subtype of neovascular AMD, however, some controversy exists about whether it should be classified as a distinct disease entity due to the difference in demographic characteristics, clinical and imaging features, disease course and treatment from other subtypes of NAMD [1]. In PCV type 1 neovascularization is associated with an abnormal branching network of vessels (branching vascular network [BVN]), with aneurysmal dilations referred to as polyps [2]. Accurate estimates of PCV prevalence are limited because of difficulties in diagnosing PCV from clinical examination and fundus photographs. In Asian patients with neovascular AMD, the proportion of PCV has been estimated to be between 20 and 60% [3]. In contrast, in Caucasians the proportion of PCV has been reported to be 8–30% of cases [4–7].

ICGA is considered the most reliable means for diagnosing PCV, however, it is not performed routinely in many parts of the world, particularly in areas where the disease is uncommon. Fluorescein angiography (FA), an imaging technique more commonly used in the diagnosis of exudative AMD, does reveal the presence of subretinal leakage and neovascularization, but lacks the ability to clearly visualize the terminal aneurysmal lesions required to make a PCV diagnosis in many cases. De Salvo et al [8] reported that based on a combination of 3 of the following 4 OCT-based signs—multiple pigment epithelial detachments (PEDs), sharp...
have reported a higher incidence of anti-VEGF resistance. The pathogenesis of PCV has been linked to choroidal con- gesture leading to an increase in choroidal thickness. The presence of a thick and hyperpermeable choroid in patients with PCV also suggests a link between PCV and the pachychoroid disease spectrum. However, it has been shown that choroidal thickness is variable in eyes with PCV, with no statistically significant difference in the clinical and imaging features and treatment outcomes between eyes with thin, medium and thick SFCT patients with PCV according to some study while others showed that in PCV eyes, thick choroids were associated with poor anatomical outcomes whereas eyes with thin choroids showed the greatest extent of improvement in anatomical but not visual outcomes. Other studies indicate the opposite, that PCV eyes with thin choroid tend to be associated with older age and show less visual improvement after the initial three consecutive anti-VEGF treat-
ments.

Results of the EVEREST-II and PLANET studies showed that anti-VEGF monotherapy (ranibizumab and aflibercept) as well as combination therapy with PDT gives excellent functional visual outcomes at 1 year, and is thus an acceptable initial treatment option in patients with symptomatic PCV. However, other studies have reported a higher incidence of anti-VEGF resistance in eyes with PCV, suggesting that alternative treatments to anti-VEGF monotherapy may be preferred in these cases.

The purpose of this study was to investigate the characteristics and response to treatment in Caucasian patients with PCV, and specifically to initial treatment with bevacizumab. Additionally, rates of treatment resistance were evaluated, as well as the correlation between choroidal thickness and treatment response.

**Methods**

A retrospective review of the electronic medical records of the ophthalmology department at the Meir Medical Center was conducted for patients diagnosed with PCV between 2005 and 2020. The study was approved by the Institutional Review Board of Meir Medical Center.

Patients treated before for PCV were excluded. Patients undergone previously ocular surgery or trauma, except for uncomplicated cataract extraction, or patients with prior vision limiting ocular conditions were excluded. All patients were 18 years or older, the diagnosis of PCV was made be a retina specialist, based on clinical examination and OCT, FA and/or ICGA.

Due to the limitations and regulations of all medical insurance carriers in Israel, which mandate first-line treatment with Bevacizumab treatment, all patients were initially treated uniformly with 3 monthly injections of bevacizumab. Patients who did not complete the first 3 months of treatment, missed or delayed injections, or who had an overall follow-up of less than 4 months after presentation were excluded. After follow-up examination after these injections, bevacizumab treatment was continued or changed at the discretion of the treating retinal specialist. Patients with incomplete records were also excluded.

Recorded parameters included demographic data, general medical history, ocular history, and lens status. Visual acuity (VA) was recorded at presentation, 1 month after 3 monthly injections of bevacizumab and at the final follow up visit. At these timepoints, OCT images were also analyzed for choroidal thickness, central macular thickness (CMT), presence of pachyvessels, presence of hemorrhages, intraretinal fluid (IRF) and subretinal fluid (SRF). Additionally, the types and numbers of different anti-VEGF injections were recorded, as well as any additional treatment, surgery or complication that occurred throughout the follow up period.

All visual acuity (VA) values were converted to the logMAR scale for statistical analysis. According to the results of Holladay and the University of Freiburg studies, counting fingers was set at 0.014/1.85, hand movements at 0.005/2.3, light perception at 0.0025/2.6 and blindness at 0.00125/2.9 (decimal/logMAR). To analyze categorical parameters chi-square tests were used, to continuous parameters between groups T tests were used. To analyze changes in VA and CMT over time Paired t tests were used. Correlations between the permanent variables were analyzed using Pearson’s correlation coefficient. Data was analyzed using SPSS for Windows version 21. A p value of 0.05 was used to show the statistically significant difference between groups.
Results
45 eyes of 43 patients who were treated in our clinic between January 1st, 2005 and December 31st, 2020 were included in the study. These included 21 (48.8%) men and 22 (51.2%) women, with a mean age at presentation of 75 ± 8.4 years (range 56–93 years). The most common systemic comorbidities were hypertension (55.8%) and diabetes mellitus (30%). The mean follow up period was 10.3 ± 6.5 months.

Analysis of clinical characteristics at presentation
Twenty-five (55.5%) eyes were phakic at presentation, and the remaining 20 (44.5%) eyes were pseudophakic. The diagnosis of PCV was made by a retina specialist based on OCT characteristics alone in 23 (51.1%) eyes, based on OCT and FA in 9 (20%) eyes, based on OCT and ICG in 3 (6.6%) eyes, and based on all three imaging modalities at presentation in 13 (22.3%) eyes.

In OCT, the mean central macular thickness was 402.1 ± 130.8 μm, mean choroidal thickness was 228 ± 76.9 μm, and pachyvessels were present in 35 (77.3%) eyes. Subretinal fluid was present in 39 (86.4%) eyes, intraretinal fluid was present in 13 (27.3%) eyes, and submacular hemorrhage was present in 5 (11.4%) eyes.

Analysis of response to initial bevacizumab treatment
All patients were treated with a fixed initial course of 3-month bevacizumab injections, and re-examined 4 weeks following the third injection. Visual acuity significantly improved from a mean of 0.59 ± 0.5 logMAR at presentation to 0.49 ± 0.5 (p = 0.009), indicating a mean gain of one line of vision after this initial treatment. Central macular thickness significantly improved from a mean of 402.1 ± 130.8 μm at presentation to 322.0 ± 96.8 μm (p = 0.00).

Subretinal fluid presence was improved from 86.4% to 47.7% (p = 0.022). Intraretinal fluid presence improved from 27.3% to 13.5% (p < 0.001) and submacular hemorrhage also improved after the three injections from 11.4%to 9.10% (p = 0.01) These results are presented in Table 1. The presence of pachyvessels did not changes during this time.

Response to treatment was compared between eyes with and without pachyvessels, as well as between eyes with and without increased choroidal thickness (analyzed with two cutoff values, above and below 250 and 300 μm). No correlation was found between the presence of pachyvessels or increased choroidal thickness and the improvement in VA, CMT or any of the other parameters (Table 2). Examples of patients with and without pachy choroid and pachyvessels are introduced in Figs. 1 and 2.

Analysis of response to treatment at the final follow up period
Mean follow up duration was 13.3 ± 6.5 months, during which the mean number of injections was 21.5 ± 14.8.

Table 1 visual acuity and OCT signs at presentation and during the follow up

|                          | At Presentation | After three bevacizumab injections | Final        |
|--------------------------|-----------------|-----------------------------------|--------------|
| VA (LogMar)              | 0.59 ± 0.5      | 0.49 ± 0.5 (p = 0.009)            | 0.59 ± 0.6   |
| CMT (μm)                 | 402.1 ± 130.8   | 322.0 ± 96.8 (p = 0.00)           | 305.2 ± 108.5|
| Choroidal thickness (μm) | 228 ± 76.9      | 216.5 ± 66.0 (p = 0.041)          | 223.1 ± 86.1 |
| SRF                      | 86.4%           | 47.70% (p = 0.022)                | 25.50% (p = 0.312)|
| IRF                      | 27.30%          | 13.60% (p = 0.00)                 | 27.90% (p = 0.079) |
| submacular hemmorhage    | 11.4%           | 9.10% (p = 0.00)                  | 0% (p = 0.00) |
| Pachyvessels             | 77.30%          | 77.30%                            | 77.30%       |

Table 2 Response to initial bevacizumab treatment regimen compared by choroidal thickness and presence of pachyvessels

|                          | Choroidal thickness above/bellow 250 μ | Choroidal thickness above/bellow 300 μ |
|--------------------------|---------------------------------------|---------------------------------------|
| Change in VA after 3 monthly injections (LogMar) | No                                   | < 250 μ                               | < 300 μ                       |
|                          | — 0.24 ± 0.38 (p = 0.19)              | — 0.13 ± 0.33 (P = 0.77)              | — 0.12 ± 0.30 (P = 0.62)     |
|                          | Yes                                   | > 250 μ                               | > 300 μ                       |
|                          | — 0.081 ± 0.32 (p = 0.19)             | — 0.10 ± 0.34 (P = 0.77)              | — 0.06 ± 0.46 (P = 0.62)     |
| Change in CMT after 3 monthly injections (μ)     | No                                   | < 250 μ                               | < 300 μ                       |
|                          | — 119.3 ± 110.2 (P = 0.24)            | — 91.6 ± 102.9 (P = 0.57)             | — 78.9 ± 103.4 (P = 0.53)    |
|                          | Yes                                   | > 250 μ                               | > 300 μ                       |
|                          | — 75.7 ± 102.4 (P = 0.24)             | — 73.85 ± 106.7 (P = 0.57)            | — 104.2 ± 110.07 (P = 0.53)  |

The bold values are patient without pachyvessels.
These included bevacizumab, aflibercept and ranibizumab that were administered following the first three initial bevacizumab injections. In 21 (46.6%) eyes, treatment was continued only with bevacizumab, 10 (22.2%) eyes were switched to aflibercept, 5 (11.1%) eyes were switched to ranibizumab and 9 (20%) eyes were treated with both aflibercept and ranibizumab after the three bevacizumab injections. Four (8.8%) eyes underwent cataract extraction during the follow up period. In 7 (15.5%) eyes foveal atrophy was noted at the final follow up.

At the final follow up, mean VA was 0.59 ± 0.6 logMAR, not significantly different than at presentation (p = 0.698). Central macular thickness was 305.2 ± 108.5 μm, remaining significantly reduced compared to the value at presentation (p < 0.001).

Rates of submacular hemorrhage remained significantly lower than at presentation (p = 0.001), but subretinal and intraretinal fluid were not. These results are presented in Table 1.

Again, there was no correlation between the presence of pachyvessels or increased choroidal thickness on the clinical or anatomical response to treatment. These analyses are presented in Table 3.

Eyes switched to aflibercept or ranibizumab injections showed better response in the central macular thickness in comparison to those in which bevacizumab injections were continued, with a mean change in CMT of 149.5 μm and 46.2 μm respectively (p = 0.013). There was no statistically significant difference between these groups regarding he change in the visual acuity and presence of IRF, SRF and hemorrhages.

No cases of endophthalmitis, vitreous hemorrhage or retinal detachment were encountered, and none of the patients required surgical intervention for complications of PCV or intravitreal injections.
Discussion
PCV is likely an underestimated and under-diagnosed condition, especially in non-Asian patients. Several studies have compared the combination of anti-VEGF with PDT against the monotherapy of anti-VEGF. The results of the EVEREST-II stated that After 12 months, combination therapy of ranibizumab plus vPDT was superior to ranibizumab monotherapy in best-corrected visual acuity and superior in complete polyp regression while requiring fewer injections, in PLANET study patient treated with aflibercept monotherapy achieved visual and/or functional improvement in more than 85% of participants. As fewer than 15% met the criteria of a suboptimal response to receive PDT, the potential benefit of adding PDT could not be determined [18, 19].

However, studies comparing the different anti-VEGF agents are scarce, and it is not clear whether any anti-VEGF agent achieves better outcomes in these cases.

Gomi et al. [23] reported 3-month outcomes of intravitreal bevacizumab in 11 eyes with PCV. After treatments of one to three injections, most eyes demonstrated reduced exudative changes, but in only one eye were the polypoidal lesions fully resolved. Lai et al. [24] also reported the efficacy of intravitreal bevacizumab therapy in 15 eyes with PCV. After the first 3 consecutive monthly 1.25 mg of intravitreal bevacizumab injections, significant improvement in both the vision and the foveal thickness was observed. Kumar et al. evaluated nine eyes of eight patients with naïve PCV who were treated with intravitreal bevacizumab monotherapy and showed that bevacizumab injection helps to improve or maintain the vision in patients with symptomatic treatment-naïve PCV [25].

The lack of head to head comparative studies of anti-VEGF monotherapy in PCV treatment makes the first regimen choice difficult. The only case series comparing two different types of anti-VEGF monotherapy included 16 eyes with PCV and reported that the visual and anatomical outcomes in terms of PED reduction were better with aflibercept compared to bevacizumab. Patients treated with aflibercept improved in BCVA by approximately 1.5 lines at 6 months, whereas those treated with bevacizumab suffered a reduction in BCVA of approximately 2 lines [26].

Yamamoto et al. reported significant improvement of BCVA at 12 months with monotherapy of aflibercept [27]. Similarly, PLANET study results showed that aflibercept monotherapy was noninferior to combination of PDT + aflibercept. The gain of visual acuity was 10.7 versus 10.8 letters [19]. Previous reports have shown that switching over to aflibercept from ranibizumab may be helpful in resistant cases [28].

In our study all patients were treated with a fixed initial regimen of three monthly bevacizumab injections, and re-examined 4 weeks following the third injection. Visual acuity significantly improved with a mean gain of one line of vision after this initial treatment. Central macular thickness significantly improved too. The presence of subretinal fluid, intraretinal fluid and submacular hemorrhage also improved after the three injections. According to our results bevacizumab monotherapy was effective with good visual and anatomical outcomes after only three monthly injections, and could be reasonably used as a first line treatment in patients with PCV.

Additionally, we found that eyes that were later switched to aflibercept or ranibizumab injections showed better response in the central macular thickness in comparison to those in which bevacizumab injections were continued. There was no statistically significant difference between these groups regarding the change in the visual acuity and presence of IRF, SRF and hemorrhages. We note that it is possible that these cases were more resistant to treatment, however, patients in which response to bevacizumab treatment was inadequate were able to be switched to aflibercept or ranibizumab. These results do not indicate that these
anti-VEGF agents are superior to bevacizumab, as their advantage was only in CMT reduction—a phenomenon well known in NVAMD as well as other conditions [25, 26].

Eyes with PCV have variable choroidal thickness, and prior studies showed conflicting results regarding the correlation between choroidal thickness, presence of pachyvessels and response to treatment [15–17]. Some studies showed that pachychoroid have better clinical outcomes and some indicate the opposite. Our results show there was no correlation between the presence of pachyvessels or increased choroidal thickness on the clinical or anatomical response to treatment.

Limitations of this study include its retrospective nature and medium sample size. However, we note that this is a relatively large series of PVC in Caucasian patients, and emphasize the strength of their all having been treated uniformly upon diagnosis. Additionally, we note that PCV diagnosis was not based on FA and ICG in all cases. The final follow up period and the switching to second line treatment were variable and not fixed in all patients.

In conclusion, this is the largest study in non-Asian PCV patients treated with fixed first line treatment regimen with intravitreal bevacizumab monotherapy. Our results indicate that this regimen achieves satisfactory visual and anatomical outcomes. However, more resistant cases in which initial results were inadequate, showed better anatomical but not visual outcomes after switching to second line treatment with ranibizumab or aflibercept. Importantly, no correlation was found between choroidal thickness or presence of pachyvessels and response to treatment, making these findings better suited to be of diagnostic rather than prognostic value.

Acknowledgements
Not relevant

Author contributions
The main author collected the data, performed the analysis, the co-authors participated in analyzing the data and writing the paper. All authors read and approved the final manuscript.

Funding
No sources of funding for the research.

Availability of data and materials
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

Declarations

Ethics approval and consent to participate
It is a retrospective study approved by the Institutional Review Board of Meir Medical Center.

Consent for publication
Not relevant.

Competing interests
There is no Competing interest for any of the authors.

Author details
1Department of Ophthalmology, Meir Medical Center, 59, Tshernichovsky St, 4428164 Kfar Saba, Israel. 2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Received: 8 October 2022   Accepted: 9 November 2022
Published online: 22 November 2022

References
1. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Prog Retin Eye Res. 2010;29(1):19–29.
2. Wong CW, Yanagi Y, Lee WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–39.
3. Li Y, You QS, Wei WB, et al. Polypoidal choroidal vasculopathy in adult Chinese: the Beijing eye study. Ophthalmology. 2014;121(11):2290–1.
4. Ciardella AP, Donsoff IM, Huang SJ, Costa DI, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49(1):25–37.
5. Lafaurie BA, Leys AM, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefe’s Arch Clin Exp Ophthalmol. 2000;238(9):752–9.
6. Liew G, Hyun-Jin HDo, Hooper C, et al. Prevalence of polypoidal choroidal vasculopathy in Caucasian patients as estimated from optical coherence tomography signs. Eye. 2021;35(3):1011–2.
7. Loentzen TD, Subhi Y, Sørensen TL. Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naive exudative age-related macular degeneration. Acta Ophthalmol. 2018;96(5):475–80.
8. De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2014;158(6):1228–1238.e1.
9. Liu R, Li J, Li Z, et al. Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography. Retina. 2016;36(4):776–86.
10. Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249:1123–8.
11. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118:940–5.
12. Kim SW, Oh J, Kwon SS, Yoo J, Huh K. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina. 2011;31(6):752–9.
13. Kuroiwa S, Tateiwa H, Hisatomi T, Ishibashi T, Yoshimura N. Pathological features of surgically excised polypoidal choroidal vasculopathy membranes. Clin Exp Ophthalmol. 2004;32:297–302.
14. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye. 2019;33:14–33.
15. Venkatesh R, Gadde SG, Pereira A, Singh V, Sangai S, Sridharan A, Bavaaharan B, Jain N, Yadav NK. Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy. Int Ophthalmol. 2020. https://doi.org/10.1007/s10792-020-01555-6.
16. Shin JY, Kwon KY, Byeon SH. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Acta Ophthalmol. 2015;93(6):524–32.
17. Kong M, Kim SM, Ham DT. Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy. PLoS ONE. 2017;12(9):1–13.
18. Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206–13.

19. Lee WX, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–93.

20. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010;150(5):666–73.

21. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009. https://doi.org/10.1016/j.ajo.2009.02.012.

22. Hatz K, Prunte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):186–94.

23. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92(1):70–3.

24. Lai TYY, Chan WM, Liu DTL, Luk FOJ, Lam DSC. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92(5):661–6.

25. Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2013;61(3):135–6.

26. Singh SR, Sahoo NK, Goud NR, Chhablani J. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2019. https://doi.org/10.4103/ijo.IJO_638_18.

27. Hara C, Sawa M, Sayanagi K, Nishida K. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Retina. 2016;36(1):37–45.

28. Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina. 2014;34(11):2192–201.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.